Name: INSMED INC (INSM) Stock
Brand: INSMED INC
Rating: 7 (3 reviews)

INSM Latest News, Press Relases and Analysis

All

Press Releases

17 hours ago - By: Bloomberg - Mentions: STX ALNY FER MPWR ...

Seagate, Alnylam Are Among Six Companies Set to Join Nasdaq 100

3 days ago - By: Zacks Investment Research - Mentions: IMVT

Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound?

9 days ago - By: Zacks Investment Research - Mentions: AMGN

Why Is Amgen (AMGN) Up 8% Since Last Earnings Report?

9 days ago - By: Insmed Incorporated

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

10 days ago - By: The Motley Fool - Mentions: STAA PTCT ACAD FOLD ...

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms

25 days ago - By: Benzinga

Peering Into Insmed Inc's Recent Short Interest

a month ago - By: Benzinga

If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today

10 days ago - By: The Motley Fool - Mentions: PTCT ACAD FOLD BMRN

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million?

11 days ago - By: BioMedWire - Mentions: SNGX PFE MRK BMY

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

24 days ago - By: Zacks Investment Research - Mentions: ALKS CRMD CSTL

Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri

25 days ago - By: Insmed Incorporated

European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

25 days ago - By: Insmed Incorporated

European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

a month ago - By: Insmed Incorporated

Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good

a month ago - By: Insmed Incorporated

Insmed To Present at November and December 2025 Investor Conferences

a month ago - By: Zacks Investment Research - Mentions: ALKS HOWL

Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake

a month ago - By: Investor's Business Daily - Mentions: ARGX UTHR LQDA

Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports

a month ago - By: Insmed Incorporated

Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update

2 months ago - By: Zacks Investment Research

Gear Up for Insmed (INSM) Q3 Earnings: Wall Street Estimates for Key Metrics

2 months ago - By: Insmed Incorporated

Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List

2 months ago - By: Zacks Investment Research

Analysts Estimate Insmed (INSM) to Report a Decline in Earnings: What to Look Out for

2 months ago - By: Insmed Incorporated

CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

2 months ago - By: Insmed Incorporated

Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025

2 months ago - By: Insmed Incorporated

INSMED INC (INSM) Stock News

INSM Latest News, Press Relases and Analysis

Seagate, Alnylam Are Among Six Companies Set to Join Nasdaq 100

Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound?

Why Is Amgen (AMGN) Up 8% Since Last Earnings Report?

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms

Peering Into Insmed Inc's Recent Short Interest

If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million?

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri

European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good

Insmed To Present at November and December 2025 Investor Conferences

Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake

Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports

Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update

Gear Up for Insmed (INSM) Q3 Earnings: Wall Street Estimates for Key Metrics

Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List

Analysts Estimate Insmed (INSM) to Report a Decline in Earnings: What to Look Out for

CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025

Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025